Exact Sciences Corp
Company Profile
Business description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Contact
5505 Endeavor Lane
MadisonWI53719
USAT: +1 608 284-5700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
7,000
Stocks News & Analysis
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
stocks
Rethinking the way we invest in Aussie tech
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.10 | 45.90 | -0.51% |
| CAC 40 | 8,122.71 | 23.24 | 0.29% |
| DAX 40 | 23,836.79 | 68.83 | 0.29% |
| Dow JONES (US) | 47,716.42 | 289.30 | 0.61% |
| FTSE 100 | 9,720.51 | 26.58 | 0.27% |
| HKSE | 26,068.05 | 209.16 | 0.81% |
| NASDAQ | 23,365.69 | 151.00 | 0.65% |
| Nikkei 225 | 49,355.82 | 898.09 | -1.79% |
| NZX 50 Index | 13,448.49 | 40.66 | -0.30% |
| S&P 500 | 6,849.09 | 36.48 | 0.54% |
| S&P/ASX 200 | 8,577.30 | 36.80 | -0.43% |
| SSE Composite Index | 3,904.90 | 16.30 | 0.42% |